On March 16, the Institute for Biotechnology and Medicine Industry (IBMI) clarified its core mission as an integrated catalyst for the industry. Amidst public discussion regarding development models, IBMI emphasized its role as a bridge between clinical medicine, technology, industry, and capital—operating not as a government agency, but as a collaborative mechanism to translate Taiwan’s innovation into market value.

• Global Benchmarking: IBMI noted that global industry leaders like BIO (US), AdvaMed, and the Japan Bioindustry Association all rely on the combined strength of corporate leaders and investment institutions.
• The "National Innovation Award" as an Accelerator: Celebrating its 20th anniversary, the award is more than a ceremony; it is a systematic vetting process. With a jury of over 100 experts, the platform provides early-stage startups with the professional credibility needed to attract "Angel" and "Series A" funding.
• The "Trio of Forces": IBMI maintains that successful internationalization requires the simultaneous alignment of clinical validation, industrial scaling, and capital support. Moving forward, the institute will continue to prioritize AI-driven smart medicine, precision health, and data applications.

Resource: 生策會：打造醫療、產業與資本平台 加速生醫創新國際化